1. Low dose total skin electron beam therapy for the management of T cell cutaneous lymphomas
- Author
-
V. Kouloulias, Kalliopi Platoni, Evangelia Papadavid, Ioannis Georgakopoulos, Efrosyni Kypraiou, Nikolaos Kelekis, Efstathios P. Efstathopoulos, George Patatoukas, Vasiliki Nikolaou, and Amdromachi Kougioumtzopoulou
- Subjects
medicine.medical_specialty ,Skin Neoplasms ,T-Lymphocytes ,T cell ,medicine.medical_treatment ,Electrons ,Dermatology ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Total skin electron beam therapy ,Mycosis Fungoides ,0302 clinical medicine ,Humans ,Medicine ,Mycosis fungoides ,business.industry ,Low dose ,General Medicine ,University hospital ,medicine.disease ,Lymphoma, T-Cell, Cutaneous ,Radiation therapy ,Regimen ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Toxicity ,Radiology ,business - Abstract
Mycosis fungoides (MF) represent the most common type of primary cutaneous lymphomas. Total skin electron beam (TSEB) therapy to a total skin administered dose of 36 Gy represents a very effective treatment regimen and its role in the management of MF is well established. Unfortunately, the issue in MF is that despite the proved effectiveness of radiation therapy, disease regress, and the main goal of TSEB treatment seems to be the prolongation of the overall response duration time. Taking into consideration the high radio-sensitivity of the disease, lower radiation doses have been tested with acceptable and comparable results. We prospectively analyzed low dose TSEB in 14 patients treated at ATTIKON University Hospital from 2011 to 2017. After a median duration of follow up time of 39 months we found that low dose TSEB is an effective treatment option, since therapeutic results are more than acceptable, with minimal toxicity. The fact that it can be repeated safely in the natural course of a "regressive" disease makes it more attractive than the standard full dose scheme of 36 Gy.
- Published
- 2020